Skip to main
GKOS
GKOS logo

Glaukos (GKOS) Stock Forecast & Price Target

Glaukos (GKOS) Analyst Ratings

Based on 20 analyst ratings
Buy
Strong Buy 55%
Buy 20%
Hold 20%
Sell 5%
Strong Sell 0%

Bulls say

Glaukos Corp has demonstrated significant improvement in operational efficiency, with an operating margin of (17.3%), a substantial increase of 2,200 basis points year-over-year, exceeding consensus expectations. The company's innovative iDose product contributed to sequential revenue growth of approximately $16 million, with projected sales of $115-120 million by 2025, highlighting its potential for future revenue expansion. Furthermore, Glaukos reported glaucoma revenues of $84 million, which surpassed consensus estimates and grew by 39% year-over-year, reflecting strong domestic and international performance, thereby positioning the company favorably for profitability in the coming years.

Bears say

Glaukos Corp reported Corneal Health revenue of $21 million, which fell short of the consensus estimate of $22 million and reflected a slowdown in growth to 2%, down from 5% in the previous quarter. The company faces significant risks, including poor sales execution, an increasingly competitive market for minimally invasive glaucoma surgery (MIGS), and reimbursement challenges, which could hinder future revenue performance. Additionally, while the gross margin decreased to 82.3%, just below expectations, substantial reductions in selling, general, and administrative expenses (SG&A) and research and development (R&D) expenses did not offset the negative growth trends and competitive pressures the company is encountering.

Glaukos (GKOS) has been analyzed by 20 analysts, with a consensus rating of Buy. 55% of analysts recommend a Strong Buy, 20% recommend Buy, 20% suggest Holding, 5% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Glaukos and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Glaukos (GKOS) Forecast

Analysts have given Glaukos (GKOS) a Buy based on their latest research and market trends.

According to 20 analysts, Glaukos (GKOS) has a Buy consensus rating as of Jul 3, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $106.10, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $106.10, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Glaukos (GKOS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.